Thermo Fisher Scientific Inc. (NYSE:TMO) Position Lifted by Marshall & Sullivan Inc. WA

Marshall & Sullivan Inc. WA lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,784 shares of the medical research company’s stock after purchasing an additional 38 shares during the period. Thermo Fisher Scientific comprises about 2.2% of Marshall & Sullivan Inc. WA’s investment portfolio, making the stock its 23rd biggest holding. Marshall & Sullivan Inc. WA’s holdings in Thermo Fisher Scientific were worth $4,570,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Legacy Investment Solutions LLC bought a new stake in Thermo Fisher Scientific in the 3rd quarter valued at about $26,000. Peterson Financial Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the third quarter valued at $27,000. HWG Holdings LP purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth about $50,000. RPg Family Wealth Advisory LLC purchased a new stake in Thermo Fisher Scientific during the third quarter valued at about $50,000. Finally, Teachers Insurance & Annuity Association of America purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth approximately $65,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded up $13.88 on Monday, reaching $556.19. The stock had a trading volume of 1,593,090 shares, compared to its average volume of 1,915,151. The firm’s 50-day moving average is $529.91 and its two-hundred day moving average is $568.06. The firm has a market capitalization of $212.74 billion, a price-to-earnings ratio of 34.87, a P/E/G ratio of 3.54 and a beta of 0.76. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same quarter in the previous year, the firm posted $5.69 EPS. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,150 shares of company stock worth $25,954,465. Company insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on TMO. Barclays lowered their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Scotiabank assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, December 23rd. They set a “sector perform” rating and a $605.00 target price for the company. StockNews.com lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, January 6th. Royal Bank of Canada decreased their price objective on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $648.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.